Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

eIF2B activator prevents neurological defects caused by a chronic integrated stress response.

Wong YL, LeBon L, Basso AM, Kohlhaas KL, Nikkel AL, Robb HM, Donnelly-Roberts DL, Prakash J, Swensen AM, Rubinstein ND, Krishnan S, McAllister FE, Haste NV, O'Brien JJ, Roy M, Ireland A, Frost JM, Shi L, Riedmaier S, Martin K, Dart MJ, Sidrauski C.

Elife. 2019 Jan 9;8. pii: e42940. doi: 10.7554/eLife.42940.

2.

Preclinical abuse liability assessment of ABT-126, an agonist at the α7 nicotinic acetylcholine receptor (nAChR).

Hudzik TJ, Basso AM, Lynch JJ 3rd, Bracken WM, Mohler EG, Kohlhaas KL, Xu H, Haig G, Gault L.

Pharmacol Biochem Behav. 2017 Jul;158:22-31. doi: 10.1016/j.pbb.2017.05.010. Epub 2017 Jun 1.

3.

Nicotinic modulation of auditory evoked potential electroencephalography in a rodent neurodevelopmental model of schizophrenia.

Kohlhaas KL, Robb HM, Roderwald VA, Rueter LE.

Biochem Pharmacol. 2015 Oct 15;97(4):482-487. doi: 10.1016/j.bcp.2015.05.011. Epub 2015 May 29.

PMID:
26032639
4.

Impact of neonatal NOS-1 inhibitor exposure on neurobehavioural measures and prefrontal-temporolimbic integration in the rat nucleus accumbens.

Dec AM, Kohlhaas KL, Nelson CL, Hoque KE, Leilabadi SN, Folk J, Wolf ME, West AR.

Int J Neuropsychopharmacol. 2014 Feb;17(2):275-87. doi: 10.1017/S1461145713000990. Epub 2013 Sep 12.

PMID:
24025168
5.

Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors.

Timmermann DB, Sandager-Nielsen K, Dyhring T, Smith M, Jacobsen AM, Nielsen EØ, Grunnet M, Christensen JK, Peters D, Kohlhaas K, Olsen GM, Ahring PK.

Br J Pharmacol. 2012 Sep;167(1):164-82. doi: 10.1111/j.1476-5381.2012.01989.x.

6.

Increased excitability of somatosensory cortex in aged humans is associated with impaired tactile acuity.

Lenz M, Tegenthoff M, Kohlhaas K, Stude P, Höffken O, Gatica Tossi MA, Kalisch T, Kowalewski R, Dinse HR.

J Neurosci. 2012 Feb 1;32(5):1811-6. doi: 10.1523/JNEUROSCI.2722-11.2012. Erratum in: J Neurosci. 2012 May 2;32(18):6411. Kowalewski, Rebecca [added].

7.

Effects of α7 nicotinic acetylcholine receptor agonists on antipsychotic efficacy in a preclinical mouse model of psychosis.

Kohlhaas KL, Bitner RS, Gopalakrishnan M, Rueter LE.

Psychopharmacology (Berl). 2012 Apr;220(4):823-33. doi: 10.1007/s00213-011-2535-6. Epub 2011 Oct 29.

PMID:
22038534
8.

In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.

Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, Marsh KC, Nikkel AL, Browman K, Radek R, Anderson DJ, Buccafusco J, Gopalakrishnan M.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):875-86. doi: 10.1124/jpet.110.167213. Epub 2010 May 26.

PMID:
20504913
9.

Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists.

Radek RJ, Kohlhaas KL, Rueter LE, Mohler EG.

Curr Pharm Des. 2010 Jan;16(3):309-22. Review.

PMID:
20109141
10.

[Life-threatening respiratory depression after pain therapy].

Gläser M, Kohlhaas K, Tegenthoff M, Maier C.

Schmerz. 2008 Dec;22(6):679-81. doi: 10.1007/s00482-008-0764-3. German.

PMID:
19050863
11.

Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties.

Tietje KR, Anderson DJ, Bitner RS, Blomme EA, Brackemeyer PJ, Briggs CA, Browman KE, Bury D, Curzon P, Drescher KU, Frost JM, Fryer RM, Fox GB, Gronlien JH, Håkerud M, Gubbins EJ, Halm S, Harris R, Helfrich RJ, Kohlhaas KL, Law D, Malysz J, Marsh KC, Martin RL, Meyer MD, Molesky AL, Nikkel AL, Otte S, Pan L, Puttfarcken PS, Radek RJ, Robb HM, Spies E, Thorin-Hagene K, Waring JF, Ween H, Xu H, Gopalakrishnan M, Bunnelle WH.

CNS Neurosci Ther. 2008 Spring;14(1):65-82. doi: 10.1111/j.1527-3458.2008.00037.x. Review.

12.

[Hepatitis B associated polyarteriitis nodosa with cerebral vasculitis].

Kohlhaas K, Brechmann T, Vorgerd M.

Dtsch Med Wochenschr. 2007 Aug;132(34-35):1748-52. German.

PMID:
17713883
13.

An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo.

Timmermann DB, Grønlien JH, Kohlhaas KL, Nielsen EØ, Dam E, Jørgensen TD, Ahring PK, Peters D, Holst D, Christensen JK, Malysz J, Briggs CA, Gopalakrishnan M, Olsen GM.

J Pharmacol Exp Ther. 2007 Oct;323(1):294-307. Epub 2007 Jul 11. Erratum in: J Pharmacol Exp Ther. 2009 Dec;331(3):1146. Chrsitensen, Jeppe K [corrected to Christensen, Jeppe K].

PMID:
17625074
14.

4-amino-5-aryl-6-arylethynylpyrimidines: structure-activity relationships of non-nucleoside adenosine kinase inhibitors.

Matulenko MA, Paight ES, Frey RR, Gomtsyan A, DiDomenico S Jr, Jiang M, Lee CH, Stewart AO, Yu H, Kohlhaas KL, Alexander KM, McGaraughty S, Mikusa J, Marsh KC, Muchmore SW, Jakob CL, Kowaluk EA, Jarvis MF, Bhagwat SS.

Bioorg Med Chem. 2007 Feb 15;15(4):1586-605. Epub 2006 Dec 20.

PMID:
17197188
15.

Synthesis and structure-activity relationships of 3,8-diazabicyclo[4.2.0]octane ligands, potent nicotinic acetylcholine receptor agonists.

Frost JM, Bunnelle WH, Tietje KR, Anderson DJ, Rueter LE, Curzon P, Surowy CS, Ji J, Daanen JF, Kohlhaas KL, Buckley MJ, Henry RF, Dyhring T, Ahring PK, Meyer MD.

J Med Chem. 2006 Dec 28;49(26):7843-53.

PMID:
17181167
16.

Graphene-based composite materials.

Stankovich S, Dikin DA, Dommett GH, Kohlhaas KM, Zimney EJ, Stach EA, Piner RD, Nguyen ST, Ruoff RS.

Nature. 2006 Jul 20;442(7100):282-6.

PMID:
16855586
17.

Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats.

Zhang M, Ballard ME, Kohlhaas KL, Browman KE, Jongen-Rêlo AL, Unger LV, Fox GB, Gross G, Decker MW, Drescher KU, Rueter LE.

Neuropsychopharmacology. 2006 Jul;31(7):1382-92. Epub 2005 Dec 14.

18.

Synthesis and biological evaluation of 6,7-disubstituted 4-aminopyrido[2,3-d]pyrimidines as adenosine kinase inhibitors.

Perner RJ, Lee CH, Jiang M, Gu YG, Didomenico S, Bayburt EK, Alexander KM, Kohlhaas KL, Jarvis MF, Kowaluk EL, Bhagwat SS.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2803-7. Epub 2005 Apr 25.

PMID:
15911258
19.

5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure-activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors.

Matulenko MA, Lee CH, Jiang M, Frey RR, Cowart MD, Bayburt EK, Didomenico S, Gfesser GA, Gomtsyan A, Zheng GZ, McKie JA, Stewart AO, Yu H, Kohlhaas KL, Alexander KM, McGaraughty S, Wismer CT, Mikusa J, Marsh KC, Snyder RD, Diehl MS, Kowaluk EA, Jarvis MF, Bhagwat SS.

Bioorg Med Chem. 2005 Jun 1;13(11):3705-20.

PMID:
15863000
20.

Loss of functional neuronal nicotinic receptors in dorsal root ganglion neurons in a rat model of neuropathic pain.

Dubé GR, Kohlhaas KL, Rueter LE, Surowy CS, Meyer MD, Briggs CA.

Neurosci Lett. 2005 Mar 7;376(1):29-34. Epub 2004 Dec 8.

PMID:
15694269
21.

Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia.

Rueter LE, Ballard ME, Gallagher KB, Basso AM, Curzon P, Kohlhaas KL.

Psychopharmacology (Berl). 2004 Nov;176(3-4):312-9. Epub 2004 Jun 4.

PMID:
15179541
22.

5,6,7-trisubstituted 4-aminopyrido[2,3-d]pyrimidines as novel inhibitors of adenosine kinase.

Perner RJ, Gu YG, Lee CH, Bayburt EK, McKie J, Alexander KM, Kohlhaas KL, Wismer CT, Mikusa J, Jarvis MF, Kowaluk EA, Bhagwat SS.

J Med Chem. 2003 Nov 20;46(24):5249-57.

PMID:
14613327
23.

Adenosine kinase inhibitors: polar 7-substitutent of pyridopyrimidine derivatives improving their locomotor selectivity.

Zheng GZ, Mao Y, Lee CH, Pratt JK, Koenig JR, Perner RJ, Cowart MD, Gfesser GA, McGaraughty S, Chu KL, Zhu C, Yu H, Kohlhaas K, Alexander KM, Wismer CT, Mikusa J, Jarvis MF, Kowaluk EA, Stewart AO.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):3041-4.

PMID:
12941329
24.

Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain.

Rueter LE, Kohlhaas KL, Curzon P, Surowy CS, Meyer MD.

Pain. 2003 Jun;103(3):269-76.

PMID:
12791433
25.

Design, synthesis, and structure-activity relationship of 6-alkynylpyrimidines as potent adenosine kinase inhibitors.

Gomtsyan A, Didomenico S, Lee CH, Matulenko MA, Kim K, Kowaluk EA, Wismer CT, Mikusa J, Yu H, Kohlhaas K, Jarvis MF, Bhagwat SS.

J Med Chem. 2002 Aug 15;45(17):3639-48.

PMID:
12166937
26.

Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor.

Jarvis MF, Yu H, McGaraughty S, Wismer CT, Mikusa J, Zhu C, Chu K, Kohlhaas K, Cowart M, Lee CH, Stewart AO, Cox BF, Polakowski J, Kowaluk EA.

Pain. 2002 Mar;96(1-2):107-18.

PMID:
11932067
27.

Synthesis and biological evaluation of clitocine analogues as adenosine kinase inhibitors.

Lee CH, Daanen JF, Jiang M, Yu H, Kohlhaas KL, Alexander K, Jarvis MF, Kowaluk EL, Bhagwat SS.

Bioorg Med Chem Lett. 2001 Sep 17;11(18):2419-22.

PMID:
11549437
28.

Pyridopyrimidine analogues as novel adenosine kinase inhibitors.

Zheng GZ, Lee C, Pratt JK, Perner RJ, Jiang MQ, Gomtsyan A, Matulenko MA, Mao Y, Koenig JR, Kim KH, Muchmore S, Yu H, Kohlhaas K, Alexander KM, McGaraughty S, Chu KL, Wismer CT, Mikusa J, Jarvis MF, Marsh K, Kowaluk EA, Bhagwat SS, Stewart AO.

Bioorg Med Chem Lett. 2001 Aug 20;11(16):2071-4.

PMID:
11514141
29.

Structure-activity studies of 5-substituted pyridopyrimidines as adenosine kinase inhibitors.

Cowart M, Lee CH, Gfesser GA, Bayburt EK, Bhagwat SS, Stewart AO, Yu H, Kohlhaas KL, McGaraughty S, Wismer CT, Mikusa J, Zhu C, Alexander KM, Jarvis MF, Kowaluk EA.

Bioorg Med Chem Lett. 2001 Jan 8;11(1):83-6.

PMID:
11140740
31.

Characterization of the effects of adenosine kinase inhibitors on acute thermal nociception in mice.

Kowaluk EA, Kohlhaas KL, Bannon A, Gunther K, Lynch JJ 3rd, Jarvis MF.

Pharmacol Biochem Behav. 1999 May;63(1):83-91.

PMID:
10340527
32.

Nitroaromatic amino acids as inhibitors of neuronal nitric oxide synthase.

Cowart M, Kowaluk EA, Daanen JF, Kohlhaas KL, Alexander KM, Wagenaar FL, Kerwin JF Jr.

J Med Chem. 1998 Jul 2;41(14):2636-42.

PMID:
9651169
33.

Induction by endotoxin of nitric oxide synthase in the rat mesentery: lack of effect on action of vasoconstrictors.

Mitchell JA, Kohlhaas KL, Sorrentino R, Warner TD, Murad F, Vane JR.

Br J Pharmacol. 1993 May;109(1):265-70.

34.

Nitric oxide synthase in ferret brain: localization and characterization.

Matsumoto T, Mitchell JA, Schmidt HH, Kohlhaas KL, Warner TD, Förstermann U, Murad F.

Br J Pharmacol. 1992 Nov;107(3):849-52.

35.

Induction of NADPH-dependent diaphorase and nitric oxide synthase activity in aortic smooth muscle and cultured macrophages.

Mitchell JA, Kohlhaas KL, Matsumoto T, Pollock JS, Förstermann U, Warner TD, Schmidt HH, Murad F.

Mol Pharmacol. 1992 Jun;41(6):1163-8.

PMID:
1377328
36.

Induced RAW 264.7 macrophages express soluble and particulate nitric oxide synthase: inhibition by transforming growth factor-beta.

Förstermann U, Schmidt HH, Kohlhaas KL, Murad F.

Eur J Pharmacol. 1992 Feb 13;225(2):161-5.

PMID:
1372563
37.

[A micromeasurement chamber for measuring colloid osmotic pressure in body fluids].

Kohlhaas K, Fiedler H.

Z Med Lab Diagn. 1988;29(3):173. German. No abstract available.

PMID:
3407293
38.

[In memoriam Dr. Robert Schmelcher].

Kohlhaas K.

Dtsch Med Wochenschr. 1968 Jun;93(23):1163-4. German. No abstract available.

PMID:
4869857

Supplemental Content

Loading ...
Support Center